Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin versus rosuvastatin for prevention of atrial fibrillation after CABG
IRCT20201028049175N2Phase 2Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Atrial fibrillation (AFib) comparing Atorvastatin arm with Rosuvastatin arm (2 arms). Primary endpoint: Frequency of post-CABG atrial fibrillation. Started Mar 2021; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20201028049175N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201028049175N2.